Horizon Pharma plc Form SC 13G/A February 17, 2015

#### **UNITED STATES**

# SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

### SCHEDULE 13G

# UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2)\*

Horizon Pharma Public Limited Company (Name of Issuer)

Ordinary Shares, nominal value \$0.0001 per share (Title of Class of Securities)

### G4617B105

(CUSIP Number)

### **December 31, 2014**

(Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- ý Rule 13d-1(c)
- o Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. G4617B105 13G Page 2 of 7 Pages 1 NAMES OF REPORTING PERSONS Christoph F. Boehringer 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* (a) (b) ý 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Germany 5 SOLE VOTING POWER 1,000,000 NUMBER OF 6 SHARED VOTING POWER **SHARES BENEFICIALLY** 2,250,000 OWNED BY 7 SOLE DISPOSITIVE POWER **EACH** REPORTING 1,000,000 PERSON WITH 8 SHARED DISPOSITIVE POWER 2,250,000 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,250,000 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN **SHARES** 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.7% 12 TYPE OF REPORTING PERSON ΙN

CUSIP No. G4617B105 13G Page 3 of 7 Pages 1 NAMES OF REPORTING PERSONS CD-Venture GmbH 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* (b) ý 3 SEC USE ONLY CITIZENSHIP OR PLACE OF ORGANIZATION Germany 5 SOLE VOTING POWER 2,250,000 NUMBER OF 6 SHARED VOTING POWER **SHARES BENEFICIALLY** OWNED BY 7 SOLE DISPOSITIVE POWER **EACH** REPORTING 2,250,000 PERSON WITH 8 SHARED DISPOSITIVE POWER 0 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,250,000 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN **SHARES** 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 1.9% 12 TYPE OF REPORTING PERSON CO

CUSIP No. G4617B105 13G Page 4 of 7 Pages Item Name of Issuer: 1(a). Horizon Pharma Public Limited Company I t e mAddress of Issuer's Principal Executive Offices: 1(b). **Adelaide Chambers** Peter Street, Dublin 8 Ireland I t e mName of Person Filing: 2(a). This Statement on Schedule 13G (this "Statement") is filed by CD-Venture GmbH ("CD-Venture") and Christoph F. Boehringer. I t e mAddress of Principal Business Office or, if none, Residence: 2(b). Bergheimer Str. 45 69115 Heidelberg Germany I t e mCitizenship: 2(c). CD-Venture is a German corporation. Mr. Boehringer is a German citizen. I t e mTitle of Class of Securities: 2(d). Ordinary Shares, nominal value \$0.0001 per share (the "Ordinary Shares") I t e mCUSIP Number: G4617B105 2(e). Ite mNot applicable. Ite mOwnership.

(a) Amount Beneficially Owned as of December 31, 2014:

# Edgar Filing: Horizon Pharma plc - Form SC 13G/A

Mr. Boehringer. Mr. Boehringer is the beneficial owner of 3,250,000 Ordinary Shares, including 2,250,000 Ordinary Shares beneficially owned by CD-Venture.

CD-Venture. CD-Venture is the beneficial owner of 2,250,000 Ordinary Shares.

The percentages used herein are based upon 118,852,790 Ordinary Shares outstanding as of November 3, 2014, as disclosed in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, as filed with the Securities and Exchange Commission on November 6, 2014.

**CUSIP No. G4617B105** 

13G

Page 5 of 7 Pages

(b) Percent of Class:

Christoph F. Boehringer

2.7%\*

CD-Venture

1.9%

- (c) Number of shares as to which such person has:
  - (i) sole power to vote or to direct the vote:

Christoph F. Boehringer 1,000,000 CD-Venture 2,250,000

(ii) shared power to vote or to direct the vote:

Christoph F. Boehringer

2,250,000\*

**CD-Venture** 

0

(iii) sole power to dispose or to direct the disposition of:

Christoph F. Boehringer 1,000,000 CD-Venture 2,250,000

(iv) shared power to dispose or direct the disposition of:

Christoph F. Boehringer

2,250,000\*

**CD-Venture** 

0

<sup>\*</sup>Includes shares beneficially owned by CD-Venture.

<sup>\*</sup>Consists of shares beneficially owned by CD-Venture with respect to which Mr. Boehringer shares the power to direct the vote.

<sup>\*</sup>Consists of shares beneficially owned by CD-Venture with respect to which Mr. Boehringer shares the power to direct the disposition.

# Edgar Filing: Horizon Pharma plc - Form SC 13G/A

CUSIP No. G4617B105

13G

Page 6 of 7 Pages

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

Item Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the 7. Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. G4617B105

13G

Page 7 of 7 Pages

## **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 17, 2015

/s/ Christoph F. Boehringer Christoph F. Boehringer

CD-Venture GmbH

By: /s/ Christoph F. Boehringer

Christoph F. Boehringer, Geschäftsführer

(Managing Director)